fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Gemfibrozil

All products: not a benefit

Lopid · DIN 00659606 · 600 mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.Discontinued July 18, 2013 · checked November 19, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2013-07-18 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lopid · DIN 00659606 Manufacturer: Pfizer Canada Inc.; listing date 2008-02-12 Health Canada: Cancelled post market since 2013-07-18 · brand LOPID 600MG · ATC C10AB04 GEMFIBROZIL · form Tablet · route Oral · ingredients GEMFIBROZIL 600 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Lopid: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00659606)

Source record
DIN 00659606: Lopid Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240600068; group id 305; item number 0668; lccId None; manufacturer id PFI Source form: Tab; strength: 600mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00659606 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9259
Interchangeable products
Apo-Gemfibrozil · DIN 01979582 · not recorded Teva-Gemfibrozil · DIN 02142074 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since July 18, 2013 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (C10A, C10AB): coverage varies; not interchangeable

  • Bezafibrate (Bezalip): general benefit
  • Fenofibrate (Lipidil): general benefit, not a benefit
  • Clofibrate (Atromid-S): not a benefit
  • Atorvastatin (Lipitor): general benefit
  • Cholestyramine resin (Questran Light 4g Pk): general benefit, not a benefit
  • Colesevelam (Lodalis): general benefit, listing status unconfirmed

9 more in the class list below

Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:06 Antilipemic Drugs

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

CLOFIBRATE

· 2 products · Listed, not a benefit · strengths: 500mg · Cap

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 84 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS TEVA-GEMFIBROZIL (gemfibrozil tablet) is indicated in adults as an adjunct to diet and other therapeutic measures for: • Treatment of patients with very high serum triglyceride levels, Fredrickson classification Type IV and V hyperlipidemias, who are at high risk of sequelae and complications (i.e. pancreatitis) from their hyperlipidemia. • Treatment of patients with hypercholesterolemia, Type IIa and IIb mixed dyslipidemias, to regulate lipid levels (reduce serum triglycerides and LDL cholesterol levels and increase HDL cholesterol). TEVA-GEMFIBROZIL alone may not be adequate therapy in some patients with familial combined hyperlipidemia with Type IIb and IV hyperlipoproteinemia. Initial therapy for hyperlipidemia should include a specific diet, weight reduction, and an exercise program and for patients with diabetes mellitus, a good diabetic control. Gemfibrozil is not indicated for the treatment of Type I hyperlipoproteinemia. 1.1 Pediatrics Pediatrics (0 to >18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics No data is available. https://pdf.hres.ca/dpd_pm/00072920.PDF PM date: November 25, 1994 Source product: TEVA-GEMFIBROZIL; DIN 02142074; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Lopid: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026